15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Relmada Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $8.00 to $19.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $12.33 sits 135% above the current $5.24. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Relmada Therapeutics Inc.
As of Jul, 6 of 6 firms rate RLMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RLMD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.25 – $-0.20 · 5 analysts · -29% YoY
Next period, 5 analysts expect Relmada Therapeutics Inc to earn $-0.21 a share (range $-0.25 – $-0.20), versus $-0.30 a year earlier. Full-year consensus is $-0.41, growing to $-0.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Relmada Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RLMD.
#1
Andrew Berens
Leerink Partners · Rank #167
Buy
$8.00+52.7% to target
Overall win rate
50%
+ Follow
#2
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$12.00+129.0% to target
Overall win rate
38%
+ Follow
#3
UE
Uy Ear
Mizuho
Buy
$19.00+262.6% to target
Coverage
—
+ Follow
#4
FH
Farzin Haque
Jefferies
Buy
$9.00+71.8% to target
Coverage
—
+ Follow
#5
Kelsey Goodwin
Piper Sandler
Buy
$12.00+129.0% to target
Coverage
—
+ Follow
RLMD stock forecast FAQ
What is RLMD's average 12-month price target?+
The 6 analysts with a live target average $12.33 for Relmada Therapeutics Inc over the next 12 months, ranging from a $19.00 high to a $8.00 low.
Is RLMD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RLMD?+
The Street-high target is $19.00 (Mizuho), and the Street-low is $8.00 (Leerink Partners). The average of all 6 active targets is $12.33.
How many Wall Street analysts cover RLMD?+
6 analysts have an active rating on Relmada Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering RLMD?+
Among analysts who currently cover RLMD, Andrew Berens of Leerink Partners has the strongest overall Quantellect track record (Rank #167). Their current call is Buy with a $8.00 target.
What is Relmada Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.25 – $-0.20) across 5 analysts. Full-year EPS is projected at $-0.41, rising to $-0.41 the following year.
How much revenue is Relmada Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading RLMD lately?+
As of Jul, 6 of 6 firms rate RLMD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RLMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
